Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?

• Alexandra Tsankof,
• Georgios Neokosmidis,
• Evgenia Koureta,
• Stavroula Veneti,
• Evangelos Cholongitas,
• Konstantinos Tziomalos

Affiliations

Alexandra Tsankof

First Propedeutic Department of Internal Medicine, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

Georgios Neokosmidis

First Propedeutic Department of Internal Medicine, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

Evgenia Koureta

Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Stavroula Veneti

First Propedeutic Department of Internal Medicine, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

Evangelos Cholongitas

Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Konstantinos Tziomalos

First Propedeutic Department of Internal Medicine, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece